Premium
Demonstration of antibody‐associated cellular cytotoxicity in patients with acute myelogenous leukemia before and after chemotherapy
Author(s) -
Fäldt R.,
Ankerst J.
Publication year - 1979
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910240105
Subject(s) - cytotoxicity , peripheral blood mononuclear cell , antibody , immunology , sephadex , cytotoxic t cell , leukemia , antibody dependent cell mediated cytotoxicity , medicine , in vitro , chemistry , biochemistry , monoclonal antibody , enzyme
This study demonstrates that a cytotoxic serum reactivity not requiring the presence of complement appears in the sera of patients with acute myelogenous leukemia. The reaction is detected upon short‐term incubation of sera in vitro with autochthonous mononuclear white blood cells from peripheral venous blood of patients at the acute stage of the disease. This reactivity was demonstrated in 18/18 patients. Generally, the cytotoxicity was low in patients at the acute stage of the disease, but increased after chemotherapy and reached the highest level at the onset of clinical remission or just before. No cytotoxicity could be demonstrated against autochthonous remission white blood cells. The serum activity could be absorbed and eluted from protein A‐Sepharose CL‐4B and was recovered in the 7S‐fraction of the sera after gel filtration on Sephadex G‐200 and ion exchange chromatography. This indicates that the demonstrated cytotoxicity is due to immunoglobulins of IgG‐class. It is believed that Fc‐receptor‐bearing cells present in the target cell preparations function as effector cells. The reaction is designated antibody‐associated cellular cytotoxicity (AACC).